Researchers reported the progression of kidney function throughout the course of IgA nephropathy. Are immunosuppressive therapies used to treat glomerular disease are related to higher cardiovascular risks? The KidneyVault Portable Renal Perfusion System has been used in human kidney transplants for the first time. Jessica Strawn explains why being aware of patients' past trauma should be of concern to kidney care providers. A study compared the risks of cardiovascular events in hospital settings among patients with CKD with and hyperkalemia. Eli Lilly ended a phase II trial of volenrelaxin in chronic kidney disease "due to a lack of foreseeable clinical benefit." Travere will submit an application to the FDA requesting approval of sparsentan for focal segmental glomerulosclerosis. Previous studies suggest a link between CKD and sleep disorders, but the nature of the association is unclear. A review and meta-analysis assessed the influence of SGLT2i therapy on clinically relevant hyperuricemic events. Using NURTuRE-CKD data, researchers studied kidney outcomes and heterogeneity of risk by primary renal diagnosis. The NKF will invest in the NoMo Kidney Pump, a continuous perfusion system to modernize kidney preservation and storage. The FDA has granted ODD and RPDD designations to ABO-101 to treat primary hyperoxaluria type 1 (PH1). Monlunabant failed in a study of its use in DKD, but Novo Nordisk had positive news about other kidney treatments in 2024. Can SZC help with RAASi maximization without resultant hyperkalemia in patients with HFrEF and CKD? Interim APPLAUSE-IgAN data showed that iptacopan was superior to placebo at reducing proteinuria at nine months. Current eligibility criteria for simultaneous heart and kidney transplantation may be subject to eGFRcr errors. How accurately and efficiently does artificial intelligence perform clinical prescreening compared with nephrologists? The WRAPSODY stent may help restore circuit patency when stenosis or occlusion occurs within the AVG or AVF for hemodialysis. Listen to part 2 of the discussion of Chapter 16 of Dr. Burton Rose's book, focused on edematous states. A MAMS platform trial will examine use of antiproteinuric and immunomodulatory therapies in glomerular diseases.